帕金森病患者认知能力下降的数据驱动序列
Andrew John Petkus1, Erin Donahue2, Michael W Jakowec2
1Department of Neurology, University of Southern California, Los Angeles, California, USA petkus@usc.edu.
Journal of neurology, neurosurgery, and psychiatry
|May 30, 2024
概括
帕金森病 (PD) 的认知障碍始于执行功能和视觉空间能力. 这些衰退的早期识别有助于针对性干预和PD患者的临床评估.
科学领域:
- 神经学 神经学
- 神经心理学 神经心理学
- 认知科学 认知科学
背景情况:
- 了解帕金森病 (PD) 认知衰退的序列对于神经病理学的洞察力和早期干预至关重要.
- 目前的评估方法需要改进,以确定PD相关认知衰退的阶段.
- 早期识别PD认知障碍对于及时和有效的干预至关重要.
研究的目的:
- 采用基于事件的建模 (EBM) 方法来确定PD认知障碍的序列.
- 通过将其衍生的认知衰退严重程度与独立查措施相关联来验证EBM.
主要方法:
- 一项涉及99名患有PD的个体的横截面观察性研究.
- 进行了神经心理测试,参与者被分为轻度认知障碍 (PD-MCI) 或微妙认知衰退组.
- 开发了一种EBM来比较认知轨迹,多变量线性回归分析了EBM阶段与查测试表现之间的关联.
主要成果:
- EBM指出,执行功能和视觉空间能力测试在PD的认知衰退序列的早期受到影响.
- 每次EBM衍生的认知衰退阶段的增加都与痴呆症评分表和蒙特利尔认知评估的表现较差相关.
结论:
- 该研究提供了关键的临床指导,用于在PD患者的神经心理评估期间优先考虑特定的认知测试.
- 这些发现强调了前额子皮层系统功能障碍对PD执行和视觉空间能力的影响.
- 这项研究有助于更准确地分期和评估帕金森病的认知衰退.
相关概念视频
Parkinson's Disease: Overview
527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
Parkinson's Disease: Treatment
257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
Alzheimer's Disease: Overview
462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Cognitive Development During Adulthood
92
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
92
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Alzheimer's Disease: Treatment
179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179


